Skip header and navigation

Refine By

161 records – page 1 of 17.

Absence of sex differences in pharmacotherapy for acute myocardial infarction.

https://arctichealth.org/en/permalink/ahliterature179138
Source
Can J Cardiol. 2004 Jul;20(9):899-905
Publication Type
Article
Date
Jul-2004
Author
Susan E Jelinski
William A Ghali
Gerry A Parsons
Colleen J Maxwell
Author Affiliation
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Source
Can J Cardiol. 2004 Jul;20(9):899-905
Date
Jul-2004
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Aged
Aged, 80 and over
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Anticoagulants - therapeutic use
Aspirin - therapeutic use
Calcium Channel Blockers - therapeutic use
Canada - epidemiology
Cohort Studies
Drug Evaluation
Drug Therapy
Female
Fibrinolytic Agents - therapeutic use
Humans
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - drug therapy
Patient Admission
Platelet Aggregation Inhibitors - therapeutic use
Sex Factors
Urban health
Abstract
Previous studies have indicated that sex differences may exist in the pharmacological management of acute myocardial infarction (AMI), with female patients being treated less aggressively.
To determine if previously reported sex differences in AMI medication use were also evident among all AMI patients treated at hospitals in an urban Canadian city.
All patients who had a primary discharge diagnosis of AMI from all three adult care hospitals in Calgary, Alberta, in the 1998/1999 fiscal year were identified from hospital administrative records (n=914). A standardized, detailed chart review was conducted. Information collected from the medical charts included sociodemographic and clinical characteristics, comorbid conditions, and cardiovascular medication use during hospitalization and at discharge.
Similar proportions of female and male patients were treated with thrombolytics, beta-blockers, angiotensin-converting enzyme inhibitors, nitrate, heparin, diuretics and digoxin. Among patients aged 75 years and over, a smaller proportion of female patients received acetylsalicylic acid in hospital than did male patients (87% versus 95%; P=0.026). Multivariable logistic regression analysis revealed that, after correction for age, use of other anticoagulants/antiplatelets and death within 24 h of admission, sex was no longer an independent predictor for receipt of acetylsalicylic acid in hospital. Medications prescribed at discharge were similar between male and female patients.
The results from this Canadian chart review study, derived from detailed clinical data, indicate that the pattern of pharmacological treatment of female and male AMI patients during hospitalization and at discharge was very similar. No sex differences were evident in the treatment of AMI among patients treated in an urban Canadian centre.
PubMed ID
15266360 View in PubMed
Less detail

Achieving optimal care for ST-segment elevation myocardial infarction in Canada.

https://arctichealth.org/en/permalink/ahliterature162934
Source
CMAJ. 2007 Jun 19;176(13):1843-4
Publication Type
Article
Date
Jun-19-2007
Author
Andrew Travers
Author Affiliation
Emergency Health Services Nova Scotia, Dartmouth, NS. traverah@gov.ns.ca
Source
CMAJ. 2007 Jun 19;176(13):1843-4
Date
Jun-19-2007
Language
English
Publication Type
Article
Keywords
Angioplasty, Balloon, Coronary
Canada
Critical Pathways
Electrocardiography
Emergency Medical Services - standards - utilization
Fibrinolytic Agents - therapeutic use
Humans
Myocardial Infarction - drug therapy - therapy
Notes
Cites: Acad Emerg Med. 2006 Jan;13(1):84-916365334
Cites: Eur Heart J. 2003 Jan;24(1):28-6612559937
Cites: Circulation. 2003 Dec 9;108(23):2851-614623806
Cites: Can J Cardiol. 2004 Sep;20(11):1075-915457302
Cites: CMAJ. 2007 Jun 19;176(13):1833-817576980
Cites: Eur Heart J. 2006 May;27(10):1146-5216624832
Cites: Eur Heart J. 2006 Jul;27(13):1530-816757491
Cites: N Engl J Med. 2006 Nov 30;355(22):2308-2017101617
Comment On: CMAJ. 2007 Jun 19;176(13):1833-817576980
PubMed ID
17576982 View in PubMed
Less detail

[Acute coronary syndrome: regional experience of rendering urgent aid at prehospital stage in Khanty-Mansi Autonomous Okrug--Yugra].

https://arctichealth.org/en/permalink/ahliterature117732
Source
Kardiologiia. 2013;53(11):17-20
Publication Type
Article
Date
2013
Author
I A Urvantseva
L V Salamatina
I A Andreeva
E V Milovanova
S I Mamedova
O R Ibragimov
A A Seitov
Source
Kardiologiia. 2013;53(11):17-20
Date
2013
Language
Russian
Publication Type
Article
Keywords
Acute Coronary Syndrome - epidemiology - therapy
Ambulatory Care - methods
Electrocardiography
Emergency Medical Services - methods
Female
Fibrinolytic Agents - therapeutic use
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Prognosis
Retrospective Studies
Russia - epidemiology
Survival Rate - trends
Thrombolytic Therapy - methods
Time Factors
Abstract
Aim of the study was assessment of efficacy of rendering urgent aid to patients with acute coronary syndrome (ACS) at prehospital stage on the territory of Khanty-Mansi Autonomous Okrug (KhMAO). The analysis showed that yearly about 5000 inhabitants of KhMAO-Yugra received prehospital medical care (30% because of acute myocardial infarction, 70% because of unstable angina). Over 3 years portion of persons requesting medical aid during first 3 hours after onset of pain attack increased 6.1%. Rate of prehospital fibrinolysis did not exceed 6.5%. Alteplase was used most often (79.7%). Late patient's appeal was among causes of rare application of thrombolytic therapy (41.8%). Most physicians responsible for prehospital care considered it necessary to refer patients with ACS directly to centers of interventional cardiology. The data obtained would promote improvement of quality of medical aid to ACS patients at prehospital stage.
PubMed ID
24654430 View in PubMed
Less detail

Acute coronary syndromes: a Canadian perspective.

https://arctichealth.org/en/permalink/ahliterature129039
Source
Can J Cardiol. 2011 Nov-Dec;27 Suppl A:S385-6
Publication Type
Article
Author
David H Fitchett
Author Affiliation
St Michael's Hospital, University of Toronto and Canadian Heart Research Centre, Toronto, Ontario, Canada. fitchettd@smh.ca
Source
Can J Cardiol. 2011 Nov-Dec;27 Suppl A:S385-6
Language
English
Publication Type
Article
Keywords
Acute Coronary Syndrome - mortality - therapy
Canada - epidemiology
Fibrinolytic Agents - therapeutic use
Humans
Platelet Aggregation Inhibitors - therapeutic use
Practice Guidelines as Topic
PubMed ID
22118041 View in PubMed
Less detail

Acute ischemic stroke and long-term outcome after thrombolysis: nationwide propensity score-matched follow-up study.

https://arctichealth.org/en/permalink/ahliterature260040
Source
Stroke. 2014 Oct;45(10):3070-2
Publication Type
Article
Date
Oct-2014
Author
Marie Louise Schmitz
Claus Z Simonsen
Heidi Hundborg
Hanne Christensen
Karsten Ellemann
Karin Geisler
Helle Iversen
Charlotte Madsen
Mary-Jette Rasmussen
Karsten Vestergaard
Grethe Andersen
Soeren P Johnsen
Source
Stroke. 2014 Oct;45(10):3070-2
Date
Oct-2014
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Denmark
Female
Fibrinolytic Agents - therapeutic use
Follow-Up Studies
Humans
Male
Middle Aged
Propensity Score
Proportional Hazards Models
Recurrence
Registries
Stroke - complications - drug therapy - mortality
Thrombolytic Therapy
Tissue Plasminogen Activator - therapeutic use
Treatment Outcome
Young Adult
Abstract
Data on long-term outcome after intravenous tissue-type plasminogen activator (tPA) in ischemic stroke are limited. We examined the risk of long-term mortality, recurrent ischemic stroke, and major bleeding, including intracranial and gastrointestinal bleeding, in intravenous tPA-treated patients when compared with intravenous tPA eligible but nontreated patients with ischemic stroke.
We conducted a register-based nationwide propensity score-matched follow-up study among patients with ischemic stroke in Denmark (2004-2011). Cox regression analysis was used to compute adjusted hazard ratios for all outcomes.
Among 4292 ischemic strokes (2146 intravenous tPA-treated and 2146 propensity score-matched nonintravenous tPA-treated patients), with a follow-up for a median of 1.4 years, treatment with intravenous tPA was associated with a lower risk of long-term mortality (adjusted hazard ratio, 0.66; 95% confidence interval, 0.49-0.88). The long-term risk of recurrent ischemic stroke (adjusted hazard ratio, 1.05; 95% confidence interval, 0.68-1.64) and major bleeding (adjusted hazard ratio, 0.59; 95% confidence interval, 0.24-1.47) did not differ significantly between the intravenous tPA-treated and nontreated patients.
Treatment with intravenous tPA in patients with ischemic stroke was associated with improved long-term survival.
PubMed ID
25190440 View in PubMed
Less detail

Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process.

https://arctichealth.org/en/permalink/ahliterature259603
Source
Chest. 2014 Sep;146(3):727-34
Publication Type
Article
Date
Sep-2014
Author
Annette Kristiansen
Linn Brandt
Thomas Agoritsas
Elie A Akl
Eivind Berge
Johan Bondi
Anders E Dahm
Lars-Petter Granan
Sigrun Halvorsen
Pål-Andre Holme
Anne Flem Jacobsen
Eva-Marie Jacobsen
Ignacio Neumann
Per Morten Sandset
Torunn Sætre
Arnljot Tveit
Trond Vartdal
Gordon Guyatt
Per Olav Vandvik
Source
Chest. 2014 Sep;146(3):727-34
Date
Sep-2014
Language
English
Publication Type
Article
Keywords
Evidence-Based Medicine - methods
Feasibility Studies
Fibrinolytic Agents - therapeutic use
Humans
Norway
Practice Guidelines as Topic - standards
Publications
Risk factors
Societies, Medical
Thrombosis - drug therapy - epidemiology - prevention & control
Time Factors
Abstract
Adaptation of guidelines for use at the national or local level can facilitate their implementation. We developed and evaluated an adaptation process in adherence with standards for trustworthy guidelines and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, aiming for efficiency and transparency. This article is the first in a series describing our adaptation of Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for a Norwegian setting.
Informed by the ADAPTE framework, we developed a five-step adaptation process customized to guidelines developed using GRADE: (1) planning, (2) initial assessment of the recommendations, (3) modification, (4) publication, and (5) evaluation. We developed a taxonomy for describing how and why recommendations from the parent guideline were modified and applied a mixed-methods case study design for evaluation of the process.
We published the adapted guideline in November 2013 in a novel multilayered format. The taxonomy for adaptation facilitated transparency of the modification process for both the guideline developers and the end users. We excluded 30 and modified 131 of the 333 original recommendations according to the taxonomy and developed eight new recommendations. Unforeseen obstacles related to acquiring a licensing agreement and procuring a publisher resulted in a 9-month delay. We propose modifications of the adaptation process to overcome these obstacles in the future.
This case study demonstrates the feasibility of a novel guideline adaptation process. Replication is needed to further validate the usefulness of the process in increasing the organizational and methodologic efficiency of guideline adaptation.
PubMed ID
25180723 View in PubMed
Less detail

Adherence and medication belief in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A nationwide population-based cohort survey.

https://arctichealth.org/en/permalink/ahliterature296214
Source
Clin Respir J. 2018 Jun; 12(6):2029-2035
Publication Type
Journal Article
Multicenter Study
Date
Jun-2018
Author
Bodil Ivarsson
Roger Hesselstrand
Göran Rådegran
Barbro Kjellström
Author Affiliation
Department of Cardiothoracic Surgery, Skåne University Hospital, Lund, Sweden.
Source
Clin Respir J. 2018 Jun; 12(6):2029-2035
Date
Jun-2018
Language
English
Publication Type
Journal Article
Multicenter Study
Keywords
Aged
Antihypertensive Agents - therapeutic use
Attitude to Health
Chronic Disease
Cross-Sectional Studies
Female
Fibrinolytic Agents - therapeutic use
Humans
Hypertension, Pulmonary - drug therapy - epidemiology - etiology
Male
Medication Adherence
Morbidity - trends
Population Surveillance
Prognosis
Pulmonary Embolism - complications - drug therapy - epidemiology
Self Report
Surveys and Questionnaires
Sweden - epidemiology
Abstract
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare diseases with a gradual decline in physical health. Adherence to treatment is crucial in these very symptomatic and life threatening diseases.
To describe PAH and CTEPH patients experience of their self-reported medication adherence, beliefs about medicines and information about treatment.
A quantitative, descriptive, national cohort survey that included adult patients from all PAH-centres in Sweden. All patients received questionnaires by mail: The Morisky Medication Adherence Scale (MMAS-8) assesses treatment-related attitudes and behaviour problems, the Beliefs about Medicines Questionnaire-Specific scale (BMQ-S) assesses the patient's perception of drug intake and the QLQ-INFO25 multi-item scale about medical treatment information.
The response rate was 74% (n?=?325), mean age 66?±?14 years, 58% were female and 69% were diagnosed with PAH and 31% with CTEPH. Time from diagnosis was 4.7?±?4.2 years. More than half of the patients (57%) reported a high level of adherence. There was no difference in the patients' beliefs of the necessity of the medications to control their illness when comparing those with high, medium or low adherence. Despite high satisfaction with the information, concerns about potential adverse effects of taking the medication were significantly related to adherence.
Treatment adherence is relatively high but still needs improvement. The multi-disciplinary PAH team should, together with the patient, seek strategies to improve adherence and prevent concern.
PubMed ID
29356440 View in PubMed
Less detail

Antithrombotic- and anticoagulation regimens in OPCAB surgery. A Nordic survey.

https://arctichealth.org/en/permalink/ahliterature171529
Source
Scand Cardiovasc J. 2005 Dec;39(6):369-74
Publication Type
Article
Date
Dec-2005
Author
Katrine H Hansen
Pia Hughes
Daniel A Steinbrüchel
Author Affiliation
Department of Cardiothoracic Surgery, H:S Rigshospitalet, Copenhagen University Hospital, Denmark. katrineha3@m1.stud.ku.dk
Source
Scand Cardiovasc J. 2005 Dec;39(6):369-74
Date
Dec-2005
Language
English
Publication Type
Article
Keywords
Anticoagulants - therapeutic use
Chemoprevention
Coronary Artery Bypass, Off-Pump - adverse effects - methods - utilization
Drug Utilization Review
Fibrinolytic Agents - therapeutic use
Finland
Health Care Surveys
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Iceland
Physician's Practice Patterns
Platelet Aggregation Inhibitors - therapeutic use
Postoperative Care - methods
Preoperative Care - methods
Questionnaires
Scandinavia
Abstract
The aim of the survey was to determine current practices for antiplatelet- and heparin therapy in OPCAB surgery in the Nordic countries.
A postal survey questionnaire was sent to all 26 departments of Cardiothoracic Surgery in Norway, Sweden, Iceland, Finland, and Denmark.
The overall response rate was 100%. The respondents performed between 130 and 1000 CABG procedures per year. Between 0.3% and 42.0% of these procedures were performed as OPCAB. Preoperative antiplatelet therapy was administered by 48%, while 96% routinely administer postoperative antiplatelet therapy. In the postoperative antiplatelet therapy there was a trend toward a combination of aspirin and low molecular weight heparin. Perioperative anticoagulation practices with heparin varied among departments as well as reversal with protamine. Eighty percent of the respondents register postoperative complications.
In the Nordic countries there is no uniform practice regarding antiplatelet therapy pre- and postoperatively as well as heparin therapy perioperatively. Dose regimens are highly variable and standard protocols have not yet been developed.
PubMed ID
16352490 View in PubMed
Less detail

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention.

https://arctichealth.org/en/permalink/ahliterature298134
Source
Eur Heart J Cardiovasc Pharmacother. 2018 01 01; 4(1):36-45
Publication Type
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Date
01-01-2018
Author
Gorav Batra
Leif Friberg
David Erlinge
Stefan James
Tomas Jernberg
Bodil Svennblad
Lars Wallentin
Jonas Oldgren
Author Affiliation
Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala Science Park, MTC, Dag Hammarskjölds väg 14B, 752 37 Uppsala, Sweden.
Source
Eur Heart J Cardiovasc Pharmacother. 2018 01 01; 4(1):36-45
Date
01-01-2018
Language
English
Publication Type
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Keywords
Aged
Aged, 80 and over
Atrial Fibrillation - complications - drug therapy
Cause of Death - trends
Female
Fibrinolytic Agents - therapeutic use
Humans
Incidence
Male
Myocardial Infarction - complications - therapy
Percutaneous Coronary Intervention
Retrospective Studies
Stroke - epidemiology - etiology - prevention & control
Sweden - epidemiology
Thrombolytic Therapy - methods
Abstract
Optimal antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI) and atrial fibrillation is uncertain. In this study, we compared antithrombotic regimes with regard to a composite cardiovascular outcome of all-cause mortality, MI or ischaemic stroke, and major bleeds.
Patients between October 2005 and December 2012 were identified in Swedish registries, n?=?7116. Landmark 0-90 and 91-365 days of outcome were evaluated with Cox-regressions, with dual antiplatelet therapy as reference. At discharge, 16.2% received triple therapy (aspirin, clopidogrel, and warfarin), 1.9% aspirin plus warfarin, 7.3% clopidogrel plus warfarin, and 60.8% dual antiplatelets. For cardiovascular outcome, adjusted hazard ratio with 95% confidence interval (HR) for triple therapy was 0.86 (0.70-1.07) for 0-90?days and 0.78 (0.58-1.05) for 91-365?days. A HR of 2.16 (1.48-3.13) and 1.61 (0.98-2.66) during 0-90 and 91-365?days, respectively, was observed for major bleeds. For aspirin plus warfarin, HR 0.82 (0.54-1.26) and 0.62 (0.48-0.79) was observed for cardiovascular outcome and 1.30 (0.60-2.85) and 1.01 (0.63-1.62) for major bleeds during 0-90 and 91-365?days, respectively. For clopidogrel plus warfarin, HR of 0.90 (0.68-1.19) and 0.68 (0.49-0.95) was observed for cardiovascular outcome and 1.28 (0.71-2.32) and 1.08 (0.57-2.04) for major bleeds during 0-90 and 91-365?days, respectively.
Compared to dual antiplatelets, aspirin or clopidogrel plus warfarin therapy was associated with similar 0-90 days and lower 91-365 days of risk of the cardiovascular outcome, without higher risk of major bleeds. Triple therapy was associated with non-significant lower risk of cardiovascular outcome and higher risk of major bleeds.
PubMed ID
29126156 View in PubMed
Less detail

[Antithrombotic therapy in operations on extracranial arteries].

https://arctichealth.org/en/permalink/ahliterature157737
Source
Vestn Khir Im I I Grek. 2008;167(1):11-3
Publication Type
Article
Date
2008
Author
G Iu Sokurenko
Iu V Luk'ianov
E V Parusova
L N Edovina
Source
Vestn Khir Im I I Grek. 2008;167(1):11-3
Date
2008
Language
Russian
Publication Type
Article
Keywords
Aged
Brain Ischemia - drug therapy - mortality - surgery
Combined Modality Therapy
Endarterectomy, Carotid - methods
Female
Fibrinolytic Agents - therapeutic use
Humans
Male
Middle Aged
Postoperative Complications - epidemiology
Russia - epidemiology
Ticlopidine - analogs & derivatives - therapeutic use
Abstract
Application of Clopidogrel in the postoperative period in patients after surgery on extracranial arteries was analyzed. The preparation was used in 56 patients. Uninterrupted intake of the drug took place during 5 to 12 months, 7+/-1.6 months on average. Stomach and duodenal ulcer was diagnosed in 11 patients (20%), 3 patients (5%) had chronic pancreatitis with periodical exacerbations and 2 patients (4%) had erythrocytemia. One bleeding requiring revision of the wound took place in the nearest postoperative period. During the whole period of observation there were no thrombotic or thromboembolic complication against the background of using plavix. In none of the patients granulocytopenia was revealed with continuous intake of plavix. An ultrasonic investigation of the operated arteries in the remote postoperative period failed to reveal hemodynamically significant restenoses of carotid arteries.
PubMed ID
18411659 View in PubMed
Less detail

161 records – page 1 of 17.